Back to Business

Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript

Business September 30, 2026 at 4:03 AM

Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript

Seeking Alpha

Read the full story at Seeking Alpha

More Stories

OpenAI named its new agent system Dots. It’s already causing confusion.

OpenAI named its new agent system Dots. It’s already causing confusion.

OpenAI may have picked an all-too-common name for its new AI agent system. Heather Diehl/Getty Images OpenAI's "dots" AI…

🇺🇸 Business Insider 18m ago

Japan’s TDK, Taiyo Yuden shares rise on AI electronics partnership

Japan’s TDK, Taiyo Yuden shares rise on AI electronics partnership

🇺🇸 Investing.com 19m ago

Fed rate hike bets for Oct fall sharply on soft data, dovish comments

Fed rate hike bets for Oct fall sharply on soft data, dovish comments

🇺🇸 Investing.com 25m ago

Your world briefing, in your pocket

Curated news from 12 countries and 10 languages. Coming soon on iOS and Android.

Coming soon on App Store Coming soon on Google Play